FDA-cleared profile

Neurophet SCALE PET

Neurophet., Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment

Clinical role
Measurement or quantification
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain
Key limitation
Keep in mind: Quantification supports clinician assessment rather than autonomous dementia diagnosis. MRI/PET processing and interpretation depend on the specified tracer and workflow.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain Input: DICOM brain 3D T1-weighted MRI and amyloid PET or FDG PET
  • Who uses it?Intended users: Medical professionals interpreting and quantitatively assessing brain MRI and PET
  • What does the software produce?Output: Brain segmentations, registered/fused images, SUV/SUVR and Centiloid measurements, color-mapped regional displays and DICOM reports
  • What is its most important limitation?Key limitation: Quantification supports clinician assessment rather than autonomous dementia diagnosis. MRI/PET processing and interpretation depend on the specified tracer and workflow.

Clinical takeaway. Clinical role: Brain MRI/PET registration, segmentation and quantitative PET assessment

Evidence takeaway. Evidence from the reviewed source record: Regulatory testing includes 64 manually referenced MRI segmentation cases, 50 MRI pairs for reproducibility, 74 paired PET/MRI cases for SUVR comparison and 176 amyloid-PET/MRI cases for Centiloid assessment. Separate family publications do not establish exact-version performance.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Brain MRI/PET registration, segmentation and quantitative PET assessment
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Measurement or quantification
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM brain 3D T1-weighted MRI and amyloid PET or FDG PET
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Brain segmentations, registered/fused images, SUV/SUVR and Centiloid measurements, color-mapped regional displays and DICOM reports
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult brain imaging assessment on medical imaging workstations
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Medical professionals interpreting and quantitatively assessing brain MRI and PET
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Quantification supports clinician assessment rather than autonomous dementia diagnosis. MRI/PET processing and interpretation depend on the specified tracer and workflow.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Regulatory testing includes 64 manually referenced MRI segmentation cases, 50 MRI pairs for reproducibility, 74 paired PET/MRI cases for SUVR comparison and 176 amyloid-PET/MRI cases for Centiloid assessment. Separate family publications do not establish exact-version performance.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Regulatory testing includes 64 manually referenced MRI segmentation cases, 50 MRI pairs for reproducibility, 74 paired PET/MRI cases for SUVR comparison and 176 amyloid-PET/MRI cases for Centiloid assessment. Separate family publications do not establish exact-version performance.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

A single clinically interpretable sensitivity for the cleared multipurpose quantification workflow was not established by the reviewed summary.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Segmentation and quantification agreement results do not establish a product-wide diagnostic specificity.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252563 MRI segmentation validation

  • DesignStandalone comparison with manual segmentation by four experts
  • PopulationBrain T1-weighted MRI test cases
  • Scopeexact submission
  • Tested versionSCALE PET submitted in K252563; numbered release not specified
  • Samplen=64
  • IndependenceIndependence not established

K252563

Preserves the baseline 64-case study and adds separate PET/registration cohorts in evidenceSummary; cohorts must not be pooled.

Comparison of Amyloid-PET Analysis Software Using 18F-Florbetaben PET in Patients with Cognitive Impairment

  • DesignRetrospective cross-software comparison
  • Population129 cognitively impaired patients: 39 Alzheimer disease and 90 non-Alzheimer disease
  • Scopeproduct family
  • Tested versionSCALE PET; exact software version not established in reviewed abstract
  • Samplen=129
  • IndependenceIndependence not established

PMID:40870879 · doi:10.3390/diagnostics15162028

Compares regional SUVR with MIMneuro and CortexID. Agreement between software packages is not exact-K252563 diagnostic accuracy.

DTI-ALPS associations with regional amyloid deposition and glucose metabolism in mild cognitive impairment and Alzheimer's disease

  • DesignObservational biomarker association study
  • Population34 Alzheimer disease, 40 mild cognitive impairment and 52 controls
  • Scopeproduct family
  • Tested versionSCALE PET used for PET quantification; exact version not established
  • Samplen=126
  • IndependenceIndependence not established

PMID:42379471 · doi:10.1016/j.neurad.2026.101586

Contextual research use, not a standalone validation of the submitted software.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM brain 3D T1-weighted MRI and amyloid PET or FDG PET

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · Neurophet SCALE PET: K252563 decision and 510(k) summary

  2. Routing

    Source context, not route validation: DICOM inputs and outputs; results can be displayed on DICOM workstations and PACS

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · Neurophet SCALE PET: K252563 decision and 510(k) summary

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Hosting topology, processing location and licensed workstation/server configuration were not established for a purchased US version.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 ·

  4. Returned objects

    Source context, not route validation: Brain segmentations, registered/fused images, SUV/SUVR and Centiloid measurements, color-mapped regional displays and DICOM reports

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · Neurophet SCALE PET: K252563 decision and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Brain segmentations, registered/fused images, SUV/SUVR and Centiloid measurements, color-mapped regional displays and DICOM reports

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · Neurophet SCALE PET: K252563 decision and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
DICOM inputs and outputs; results can be displayed on DICOM workstations and PACS
  • Exact FDA submission
  • Checked 2026-09-05
Security
Neurophet announced on its press page and company history page that it obtained international information security certifications ISO 27001 and ISO 27701 (Korean-language pages).
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement (Korean-language press release headline and history entry on the owning domain); the press page body did not render readable text on 2026-10-27 and certificates were not read. Exact-release scope is not established.

Family quantitative PET workflow

Vendor describes automated registration and SUVR/Centiloid analysis

product family · checked 2026-09-05

The current Korean page also describes PET/CT and PET-only workflows; those are not promoted as K252563 MRI/PET capabilities.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252563
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Existing broad catalog category retained because the controlled vocabulary has no combined MRI/PET entry. The summary specifically requires 3D T1-weighted MRI and amyloid or FDG PET; this is not an unknown input modality.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
20Fields reviewed
11Source classes checked
2Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Both PubMed records name SCALE PET and are retained as family contextual studies. NCT07417540 metadata identifies a Neurophet quantitative brain PET evaluation, but live registry returned a JavaScript shell; methods, outcomes and exact version remain unverified. The current discovery snapshot contains 2 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, peer reviewed publication, trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    Reviewed product material did not establish an exact-version US license or per-analysis rate.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Neurophet AQUA reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Results were Japan or Korea coverage news and vendor pages, not US coding or payment for this product. This records what was found, not that none exists.

  • Deployment: Not verified - checked 2026-09-05 - Exact FDA submission

    Hosting topology, processing location and licensed workstation/server configuration were not established for a purchased US version.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Tracer-specific onboarding and acceptance criteria require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Update validation and site-level tracer/registration failure monitoring remain unestablished.

11 sources - 3 history items

Source ledger

  1. K252563 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Neurophet SCALE PET model card (K252563)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Neurophet SCALE PET: K252563 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, evidence, implementation

  8. Neurophet SCALE PET solutions

    Neurophet - Accessed 2026-09-05

    Scope: implementation

  9. Comparison of Amyloid-PET Analysis Software Using 18F-Florbetaben PET in Patients with Cognitive Impairment

    Diagnostics / PubMed - Published 2025-08-13 - Accessed 2026-09-05

    Scope: evidenceStudies

  10. DTI-ALPS associations with regional amyloid deposition and glucose metabolism in mild cognitive impairment and Alzheimer's disease

    Journal of Neuroradiology / PubMed - Published 2026-06-30 - Accessed 2026-09-05

    Scope: evidenceStudies

  11. Neurophet: ISO 27001 and ISO 27701 Certification Announcement

    Neurophet - Accessed 2026-10-27

    Scope: security

Research history

  1. K252563 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260316

CMN Capillary Function with Oncology Virtual Expert

Cercare Medical A/S

Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-06-22
FDA-cleared K252496

Neurophet AQUA AD Plus

Neurophet., Inc.

Authorized purpose: Quantitative brain MRI and amyloid-PET analysis, including volumetric reference-percentile comparison and SUVR quantification, to support physician clinical evaluation.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-01-29
FDA-cleared K241083

SIS System

Surgical Information Sciences, Inc.

Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, GPi, and Vim, and segment implanted leads for surgical review.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2024-06-14
FDA-cleared K230977

SIS System

Surgical Information Sciences, Inc.

Authorized purpose: SIS System fuses clinical brain MRI with postoperative CT to visualize DBS anatomy, localize STN, GPe, and GPi, and segment implanted leads for professional review.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2023-05-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history